DWTX – dogwood therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]
Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
Form 4 Dogwood Therapeutics, For: Dec 04 Filed by: Walsh Angela
Form 4 Dogwood Therapeutics, For: Dec 04 Filed by: Gendreau Roger Michael
Form 4 Dogwood Therapeutics, For: Dec 04 Filed by: Duncan Gregory Scott
Form 4 Dogwood Therapeutics, For: Dec 04 Filed by: Grosswald Ralph
Form 8-K Dogwood Therapeutics, For: Nov 28
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.